查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1728071

多癌種篩檢市場－全球產業規模、佔有率、趨勢、機會和預測，按檢測類型、技術、樣本、方法、癌症類型、應用、最終用戶、地區和競爭細分，2020 年至 2030 年

Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By Sample, By Method, By Cancer Type, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球多癌症篩檢市場價值為 14.1 億美元，預計到 2030 年將達到 32.9 億美元，預測期內複合年成長率為 15.12%。由於人們對早期癌症檢測的認知不斷提高、各種癌症發生率不斷上升以及基因組分析技術的進步，市場正在迅速擴張。醫療保健系統擴大投資於非侵入性早期檢測方法，包括液體活體組織切片、下一代定序 (NGS) 和 AI 整合生物資訊學平台，以便同時篩檢多種癌症。

市場概覽
預測期 2026-2030
2024年市場規模 14.1億美元
2030年市場規模 32.9億美元
2025-2030 年複合年成長率 15.12%
成長最快的領域 胃腸道
最大的市場 北美洲

政府支持的舉措，例如「癌症登月計畫」和其他國際資助項目，正在進一步加速研究和商業部署。診斷開發人員和學術機構之間的策略合作夥伴關係正在促進強力的臨床驗證和更廣泛的應用。這些努力，加上向預防保健和人口篩檢策略的轉變，正在推動已開發市場和新興市場多癌症早期檢測 (MCED) 測試的強勁發展勢頭。

關鍵市場促進因素

慢性病盛行率不斷上升

主要市場挑戰

缺乏標準化和臨床驗證

主要市場趨勢

液體切片檢查與基因組技術的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球多癌種篩檢市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依測試類型（實驗室開發測試 (LDT)、體外診斷 (IVD)）
    • 依技術（次世代定序 (NGS)、聚合酶鍊式反應 (PCR)、免疫組織化學 (IHC)、螢光原位雜合技術 (FISH)、其他）
    • 依樣本（組織、血液、唾液和口腔拭子等）
    • 依方法（DNA、RNA、蛋白質）
    • 依癌症類型（乳癌和婦科癌、胃腸道癌、內分泌癌、泌尿生殖系統癌、皮膚癌、腦/神經系統癌、肉瘤、血液系統惡性腫瘤、肺癌、頭頸癌、其他癌症類型）
    • 按應用（臨床、研究）
    • 按最終使用者（醫院、診斷和臨床實驗室、學術研究機構等）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美多癌症篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲多癌種篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區多癌症種篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美多癌篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲多癌症篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Agilent Technologies, Inc.
  • Atara Biotherapeutics, Inc.
  • Burning Rock Biotech Limited
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Konica Minolta, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 15592

The Global Multicancer Screening Market was valued at USD 1.41 billion in 2024 and is projected to reach USD 3.29 billion by 2030, registering a CAGR of 15.12% during the forecast period. The market is expanding rapidly, supported by heightened awareness around early cancer detection, growing incidence rates of various cancer types, and technological advancements in genomic analysis. Healthcare systems are increasingly investing in non-invasive early detection methods, including liquid biopsy, next-generation sequencing (NGS), and AI-integrated bioinformatics platforms that facilitate screening for multiple cancers simultaneously.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.41 Billion
Market Size 2030USD 3.29 Billion
CAGR 2025-203015.12%
Fastest Growing SegmentGastrointestinal
Largest MarketNorth America

Government-backed initiatives, such as the Cancer Moonshot program and other international funding projects, are further accelerating research and commercial deployment. Strategic partnerships between diagnostic developers and academic institutions are fostering robust clinical validation and broader adoption. These efforts, combined with the shift toward preventive care and population-level screening strategies, are driving strong momentum for multicancer early detection (MCED) tests in both developed and emerging markets.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The growing global burden of cancer continues to be a major driver for the multicancer screening market. Rising incidences of cancer types such as breast, lung, colorectal, prostate, and stomach cancer are fueling the demand for comprehensive screening solutions. For example, in 2023 alone, approximately 300,590 new cases of breast cancer were diagnosed in the U.S. According to the World Health Organization, global cancer data from 2020 showed 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and over 1 million cases each for colon, prostate, skin (non-melanoma), and stomach cancers.

Countries like Denmark, Ireland, and Australia continue to record some of the highest cancer incidence rates globally, indicating a pressing need for early, accurate, and efficient detection methods. Multicancer screening platforms offer the potential to identify a wide array of cancers at earlier stages, improving prognosis and reducing mortality rates. As cancer rates rise, especially in aging and urbanizing populations, the need for reliable MCED solutions will continue to grow, reinforcing market demand.

Key Market Challenges

Lack of Standardization and Clinical Validation

One of the primary challenges faced by the multicancer screening market is the lack of harmonized standards and comprehensive clinical validation for newer screening tests. Despite significant innovation, the absence of universal testing protocols and diagnostic benchmarks across geographies leads to inconsistent results, limiting test reliability. Without standardized procedures, healthcare providers may remain cautious in adopting multicancer screening technologies.

Moreover, many MCED platforms lack validation through large-scale clinical trials, which are essential for establishing clinical efficacy, sensitivity, and specificity. Regulatory agencies demand substantial evidence before approving these tools for widespread use. Without such validation, uncertainty persists regarding the accuracy and practical application of these tests in real-world settings. This slows down market adoption and hinders regulatory acceptance, particularly in diverse population groups with varying risk profiles.

Key Market Trends

Integration of Liquid Biopsy and Genomic Technologies

A prominent trend shaping the multicancer screening landscape is the convergence of liquid biopsy and advanced genomic technologies. Liquid biopsy methods analyze biomarkers such as circulating tumor DNA (ctDNA), RNA, and exosomes from blood or other fluids, offering a minimally invasive approach to early cancer detection. These techniques allow for cancer identification even before symptoms emerge, and they support ongoing disease monitoring and treatment assessment.

When paired with high-throughput genomic tools such as next-generation sequencing (NGS), the accuracy and scope of liquid biopsy expand significantly. NGS enables comprehensive mutation analysis and enhances the detection of multiple cancer types from a single sample. As these technologies become more cost-effective and refined, their adoption is increasing for large-scale, multi-cancer screening. This integration improves test efficiency, reduces patient burden, and supports broader implementation of population-wide cancer detection programs.

Key Market Players

  • Agilent Technologies, Inc.
  • Atara Biotherapeutics, Inc.
  • Burning Rock Biotech Limited
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Konica Minolta, Inc.

Report Scope

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multicancer Screening Market, By Test Type:

  • Laboratory Developed Tests (LDTs)
  • In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Fluorescence In-Situ Hybridization (FISH)
  • Others

Multicancer Screening Market, By Sample:

  • Tissue
  • Blood
  • Saliva and Buccal Swab
  • Others

Multicancer Screening Market, By Method:

  • DNA
  • RNA
  • Proteins

Multicancer Screening Market, By Cancer Type:

  • Breast and Gynecologic
  • Gastrointestinal
  • Endocrine
  • Genitourinary
  • Skin
  • Brain/Nervous System
  • Sarcoma
  • Hematological Malignancies
  • Lung
  • Head and Neck
  • Other Cancer Types

Multicancer Screening Market, By Application:

  • Clinical
  • Research

Multicancer Screening Market, By End User:

  • Hospitals
  • Diagnostic and Clinical Laboratories
  • Academic Research Institutions
  • Others

Multicancer Screening Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations

Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
    • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others)
    • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, Others)
    • 5.2.4. By Method (DNA, RNA, Proteins)
    • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types)
    • 5.2.6. By Application (Clinical, Research)
    • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others)
    • 5.2.8. By Company (2024)
    • 5.2.9. By Region
  • 5.3. Market Map

6. North America Multicancer Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Sample
    • 6.2.4. By Method
    • 6.2.5. By Cancer Type
    • 6.2.6. By Application
    • 6.2.7. By End User
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Multicancer Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Sample
        • 6.3.1.2.4. By Method
        • 6.3.1.2.5. By Cancer Type
        • 6.3.1.2.6. By Application
        • 6.3.1.2.7. By End User
    • 6.3.2. Mexico Multicancer Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Sample
        • 6.3.2.2.4. By Method
        • 6.3.2.2.5. By Cancer Type
        • 6.3.2.2.6. By Application
        • 6.3.2.2.7. By End User
    • 6.3.3. Canada Multicancer Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Sample
        • 6.3.3.2.4. By Method
        • 6.3.3.2.5. By Cancer Type
        • 6.3.3.2.6. By Application
        • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Sample
    • 7.2.4. By Method
    • 7.2.5. By Cancer Type
    • 7.2.6. By Application
    • 7.2.7. By End User
    • 7.2.8. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Multicancer Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Sample
        • 7.3.1.2.4. By Method
        • 7.3.1.2.5. By Cancer Type
        • 7.3.1.2.6. By Application
        • 7.3.1.2.7. By End User
    • 7.3.2. Germany Multicancer Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Sample
        • 7.3.2.2.4. By Method
        • 7.3.2.2.5. By Cancer Type
        • 7.3.2.2.6. By Application
        • 7.3.2.2.7. By End User
    • 7.3.3. United Kingdom Multicancer Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Sample
        • 7.3.3.2.4. By Method
        • 7.3.3.2.5. By Cancer Type
        • 7.3.3.2.6. By Application
        • 7.3.3.2.7. By End User
    • 7.3.4. Italy Multicancer Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Sample
        • 7.3.4.2.4. By Method
        • 7.3.4.2.5. By Cancer Type
        • 7.3.4.2.6. By Application
        • 7.3.4.2.7. By End User
    • 7.3.5. Spain Multicancer Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Sample
        • 7.3.5.2.4. By Method
        • 7.3.5.2.5. By Cancer Type
        • 7.3.5.2.6. By Application
        • 7.3.5.2.7. By End User

8. Asia-Pacific Multicancer Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Sample
    • 8.2.4. By Method
    • 8.2.5. By Cancer Type
    • 8.2.6. By Application
    • 8.2.7. By End User
    • 8.2.8. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Multicancer Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Sample
        • 8.3.1.2.4. By Method
        • 8.3.1.2.5. By Cancer Type
        • 8.3.1.2.6. By Application
        • 8.3.1.2.7. By End User
    • 8.3.2. India Multicancer Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Sample
        • 8.3.2.2.4. By Method
        • 8.3.2.2.5. By Cancer Type
        • 8.3.2.2.6. By Application
        • 8.3.2.2.7. By End User
    • 8.3.3. South Korea Multicancer Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Sample
        • 8.3.3.2.4. By Method
        • 8.3.3.2.5. By Cancer Type
        • 8.3.3.2.6. By Application
        • 8.3.3.2.7. By End User
    • 8.3.4. Japan Multicancer Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Sample
        • 8.3.4.2.4. By Method
        • 8.3.4.2.5. By Cancer Type
        • 8.3.4.2.6. By Application
        • 8.3.4.2.7. By End User
    • 8.3.5. Australia Multicancer Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Sample
        • 8.3.5.2.4. By Method
        • 8.3.5.2.5. By Cancer Type
        • 8.3.5.2.6. By Application
        • 8.3.5.2.7. By End User

9. South America Multicancer Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Sample
    • 9.2.4. By Method
    • 9.2.5. By Cancer Type
    • 9.2.6. By Application
    • 9.2.7. By End User
    • 9.2.8. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Multicancer Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Sample
        • 9.3.1.2.4. By Method
        • 9.3.1.2.5. By Cancer Type
        • 9.3.1.2.6. By Application
        • 9.3.1.2.7. By End User
    • 9.3.2. Argentina Multicancer Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Sample
        • 9.3.2.2.4. By Method
        • 9.3.2.2.5. By Cancer Type
        • 9.3.2.2.6. By Application
        • 9.3.2.2.7. By End User
    • 9.3.3. Colombia Multicancer Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Sample
        • 9.3.3.2.4. By Method
        • 9.3.3.2.5. By Cancer Type
        • 9.3.3.2.6. By Application
        • 9.3.3.2.7. By End User

10. Middle East and Africa Multicancer Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Technology
    • 10.2.3. By Sample
    • 10.2.4. By Method
    • 10.2.5. By Cancer Type
    • 10.2.6. By Application
    • 10.2.7. By End User
    • 10.2.8. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Multicancer Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Sample
        • 10.3.1.2.4. By Method
        • 10.3.1.2.5. By Cancer Type
        • 10.3.1.2.6. By Application
        • 10.3.1.2.7. By End User
    • 10.3.2. Saudi Arabia Multicancer Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Sample
        • 10.3.2.2.4. By Method
        • 10.3.2.2.5. By Cancer Type
        • 10.3.2.2.6. By Application
        • 10.3.2.2.7. By End User
    • 10.3.3. UAE Multicancer Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Sample
        • 10.3.3.2.4. By Method
        • 10.3.3.2.5. By Cancer Type
        • 10.3.3.2.6. By Application
        • 10.3.3.2.7. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Agilent Technologies, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Atara Biotherapeutics, Inc.
  • 14.3. Burning Rock Biotech Limited
  • 14.4. Exact Sciences Corporation
  • 14.5. F. Hoffmann-La Roche Ltd.
  • 14.6. Fulgent Genetics, Inc.
  • 14.7. Genecast Biotechnology Co., Ltd.
  • 14.8. Guardant Health, Inc.
  • 14.9. Illumina, Inc.
  • 14.10. Konica Minolta, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer